Complications of intravitreal injections - Own experience;Powikłania po iniekcjach do komory ciała szklistego - Doœwiadczenia własne

Klinika Oczna

Volumn 113, Issue 4-6, 2011, Pages 127-131

  Jamrozy Witkowska, Agnieszka ^a   Kowalska, Katarzyna ^a   Jankowska Lech, Irmina ^a   Terelak Borys, Barbara ^a   Nowosielska, Agnieszka ^a   Grabska Liberek, Iwona ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Anti VEGF agents; Complications; Intravitreal injection; Triamcinolone acetate

Indexed keywords

ANTIINFLAMMATORY AGENT; APTAMER; BEVACIZUMAB; GLUCOCORTICOID; MONOCLONAL ANTIBODY; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CONJUNCTIVA DISEASE; DIABETIC RETINOPATHY; DRUG EFFECT; ENDOPHTHALMITIS; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; INTRAOCULAR HEMORRHAGE; INTRAOCULAR HYPERTENSION; INTRAVITREAL DRUG ADMINISTRATION; IRIS DISEASE; MALE; MIDDLE AGED; POLAND; RETINA DISEASE; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; RISK FACTOR; VISUAL ACUITY;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CONJUNCTIVAL DISEASES; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; EYE DISEASES; EYE HEMORRHAGE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INTRAVITREAL INJECTIONS; IRIS DISEASES; MACULAR DEGENERATION; MACULAR EDEMA; MALE; MIDDLE AGED; OCULAR HYPERTENSION; POLAND; RETINAL DISEASES; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; RISK FACTORS; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 80053642041     PISSN: 00232157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rosenfeld PJ, Brown DM, Heier JS et al. MARINA study group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355,1419-1431.
2. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al.: Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PA-CORES). Graefes Arch Clin Exp Ophthalmol 2008,246,81-87.
3. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guy-er DR: VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004, 35, 2805-2816.
4. Jonas JB: Intravitreal triamcinolone acetonide: A change in a paradigm. Ophthalmic Res 2006, 38, 218-245.
5. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis Al, Liotsou A, Vergados I: Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2000 injections. Retina 2009, 29,313-318.
6. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG et al.: Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007,114,743-750.
7. Fung AE, Rosenfeld PJ, Reichel E: The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthamol 2006, 90,1344-1349.
8. Regillo CD, Brown DM, Abraham P et al.: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008,145, 239-248.
9. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N: Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009, 40, 293-295.
10. Jalil A, Fenerty C, Charles S: Intravitreal bevacizumab (Avastin) causing acute glaucoma: An reported complication. Eye 2007, 21,1541.
11. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005,112, 593-598.
12. Ciardella AP, Klancnik J, Schiff W et al.: Intravitreal triamcinolone for the treatment of refractory diabetic macular edema with hard exudates: An optical coherence tomography study. Br J Ophthalmol 2004, 88,1131-1136.
13. Chieh JJ, Roth DB, Liu M, Belmont J, Nelson M, Regillo C, Mar-tidis A: Intravitreal triamcinolone acetonide for diabetic macular edema. Retina 2005, 25, 828-834.
14. Martidis A, Duker JS, Greenberg PB et al.: Intravitreal triamcinolone for refractory macular edema. Ophthalmology 2000, 109, 920-927.
15. Gillies MC, Sutter FK, Simpson JM et al.: Intravitreal triamcinolone for refractory diabetic macular edema: two year results of a double-masked, placebo-controlled randomized clinical trial. Ophthalmology 2006,113,1533-1538.
16. Cunningham MA, Edelman JL, Kaushal S: Intravitreal steroids for macular edema: the past, the present and the future. Surv Ophthalmol 2008, 53,139-149.
17. Jager RD, Aiello P, Patel SC, Cunningham ET: Risks of intravitre-ous injection: A comprehensive review. Retina 2004, 24, 676-698.
18. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA: Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003, 121, 1279-1282.
19. Ta CN: Minimizing risk of endophthalmitis following intravitreu-ous injections. Retina 2004, 24, 699-705.
20. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM: Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009, 29, 601-605.
21. Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, Klancnik J, Cooney M: Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injection in an office setting. Am J Ophthalmol 2008,145, 879-882.
22. Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, Hollands H, Sharma S: Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008, 28,1395-1399.
23. Mason JO 3rd, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO, Yunker JJ, Vail RS: Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008, 28, 564-567.
24. Jonas JB, Spandau UH, Schlichtenbrede F: Shor-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 2008, 22, 590-591.
25. Jonas JB, Degenring RF, Vossmerbaeumer U, Kamppeter BA: Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide. Eur J Ophthalmol 2005, 15, 462-464.
26. Gillies MC, Kuzniarz M, Craig J et al.: Intravitreal triamcinolo-ne- induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005,112,139-143.